50.7% response rate, 23-month median duration: Despite promising phase 3 ALLELE trial data, FDA cites manufacturing issues in rejecting #Tabelecleucel for EBV+ #PTLD. A resubmission is planned. Details:
#Tabelecleucel #PTLD